Federal Register #2026-19803

DEA Notice: Irvine Labs, Inc. Application to Manufacture Schedule I Controlled Substances for Research

This notice concerns the Drug Enforcement Administration (DEA) under the Department of Justice and Irvine Labs, Inc.'s application to register as a bulk manufacturer of controlled substances. - Government Buyer: - U.S. Department of Justice, Drug Enforcement Administration (DEA) - OEM/Vendor: - Irvine Labs, Inc. - Products/Services Requested: - Registration to manufacture Schedule I controlled substances for research and development and distribution to research customers - Substances include: - Ibogaine (7260) - Lysergic acid diethylamide (LSD, 7315) - Mescaline (7381) - Peyote (7415) - Diethyltryptamine (7434) - Dimethyltryptamine (7435) - Psilocybin (7437) - Psilocyn (7438) - Unique/Notable Requirements: - Registration is for internal R&D and distribution to research customers only - No other activities for these substances are authorized under this registration - Public comments and hearing requests are invited - No specific product quantities or part numbers are provided, as this is a registration notice, not a procurement for goods or services

Description

Irvine Labs, Inc. has applied to be registered as a bulk manufacturer of controlled substances. The application includes plans to bulk manufacture listed controlled substances for research and development purposes internally and for distribution to research customers. Comments on the application can be submitted electronically or in writing by November 27, 2026. A hearing request can also be filed by the same date. The notice is published by the Drug Enforcement Administration under the Justice Department.

View original listing